Risk-Benefit Balance of Simultaneous Gastric Bypass or Sleeve Gastrectomy and Concomitant Cholecystectomy: A Comprehensive Nationwide Cohort of 289,627 Patients.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
6
10
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
To assess the relevance of concomitant laparoscopic metabolic bariatric surgery (MBS) and cholecystectomy. Because of the massive weight loss it induces, MBS is associated with an increase in the frequency of gallstones. However, no consensus yet exists on the risk-to-benefit ratio of a concomitant cholecystectomy (CC) during MBS to prevent long-term biliary complications. This nationwide retrospective cohort research was conducted in 2 parts using information from a national administrative database (PMSI). The 90-day morbidity of MBS with or without CC was first compared in a matched trial (propensity score). Second, we observed medium-term biliary complication following MBS when no CC had been performed during MBS up to 9 years after MBS (minimum 18 months). Between 2013 and 2020, 289,627 patients had a sleeve gastrectomy (SG: 70%) or a gastric bypass (GBP: 30%). The principal indications of CC were symptomatic cholelithiasis (79.5%) or acute cholecystitis (3.6%). Prophylactic CC occurred only in 15.5% of the cases. In our matched-group analysis, we included 9323 patients in each arm. The complication rate at day 90 after surgery was greater in the CC arm [odds ratio=1.3 (1.2-1.5), P <0.001], independently of the reason of the CC. At 18 months, there was a 0.1% risk of symptomatic gallstone migration and a 0.08% risk of biliary pancreatitis. At 9 years, 20.5±0.52% of patients underwent an interval cholecystectomy. The likelihood of interval cholecystectomy decreased from 5.4% per year to 1.7% per year after the first 18 months the whole cohort, risk at 18 months of symptomatic gallstone migration was 0.1%, of pancreatitis 0.08%, and of angiocholitis 0.1%. CC during SG and GBP should be avoided. In the case of asymptomatic gallstones after MBS, prophylactic cholecystectomy should not be recommended.
Sections du résumé
OBJECTIVE
To assess the relevance of concomitant laparoscopic metabolic bariatric surgery (MBS) and cholecystectomy.
BACKGROUND
Because of the massive weight loss it induces, MBS is associated with an increase in the frequency of gallstones. However, no consensus yet exists on the risk-to-benefit ratio of a concomitant cholecystectomy (CC) during MBS to prevent long-term biliary complications.
METHODS
This nationwide retrospective cohort research was conducted in 2 parts using information from a national administrative database (PMSI). The 90-day morbidity of MBS with or without CC was first compared in a matched trial (propensity score). Second, we observed medium-term biliary complication following MBS when no CC had been performed during MBS up to 9 years after MBS (minimum 18 months).
RESULTS
Between 2013 and 2020, 289,627 patients had a sleeve gastrectomy (SG: 70%) or a gastric bypass (GBP: 30%). The principal indications of CC were symptomatic cholelithiasis (79.5%) or acute cholecystitis (3.6%). Prophylactic CC occurred only in 15.5% of the cases. In our matched-group analysis, we included 9323 patients in each arm. The complication rate at day 90 after surgery was greater in the CC arm [odds ratio=1.3 (1.2-1.5), P <0.001], independently of the reason of the CC. At 18 months, there was a 0.1% risk of symptomatic gallstone migration and a 0.08% risk of biliary pancreatitis. At 9 years, 20.5±0.52% of patients underwent an interval cholecystectomy. The likelihood of interval cholecystectomy decreased from 5.4% per year to 1.7% per year after the first 18 months the whole cohort, risk at 18 months of symptomatic gallstone migration was 0.1%, of pancreatitis 0.08%, and of angiocholitis 0.1%.
CONCLUSION
CC during SG and GBP should be avoided. In the case of asymptomatic gallstones after MBS, prophylactic cholecystectomy should not be recommended.
Identifiants
pubmed: 37476980
doi: 10.1097/SLA.0000000000006039
pii: 00000658-202311000-00013
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
725-731Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Pineda O, Maydón HG, Amado M, et al. A prospective study of the conservative management of asymptomatic preoperative and postoperative gallbladder disease in bariatric surgery. Obes Surg. 2017;27:148–153.
Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–234.
Caiazzo R, Lassailly G, Leteurtre E, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014;260:893–899.
Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12:1347–1352.
Sneineh MA, Harel L, Elnasasra A, et al. Increased incidence of symptomatic cholelithiasis after bariatric roux-en-Y gastric bypass and previous bariatric surgery: a single center experience. Obes Surg. 2020;30:846–850.
Mason EE, Renquist KE. Gallbladder management in obesity surgery. Obes Surg. 2002;12:222–229.
Dirnberger AS, Schneider R, Slawik M, et al. Management of gallstone disease prior to and after metabolic surgery: a single-center observational study. Surg Obes Relat Dis. 2022;18:182–188.
Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022;18:1345–1356.
Doulamis IP, Michalopoulos G, Boikou V, et al. Concomitant cholecystectomy during bariatric surgery: the jury is still out. Am J Surg. 2019;218:401–410.
Yao XI, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst. 2017;109:djw323.
Caiazzo R, Baud G, Clément G, et al. Impact of centralized management of bariatric surgery complications on 90-day mortality. Ann Surg. 2018;268:831–837.
Wanjura V, Sandblom G, Österberg J, et al. Cholecystectomy after gastric bypass—incidence and complications. Surg Obes Relat Dis. 2017;13:979–987.
Xia C, Wang M, Lv H, et al. The safety and necessity of concomitant cholecystectomy during bariatric surgery in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2021;31:5418–5426.
Tustumi F, Bernardo WM, Santo MA, et al. Cholecystectomy in patients submitted to bariatric procedure: a systematic review and meta-analysis. Obes Surg. 2018;28:3312–3320.
Martens EP, Pestman WR, De Boer A, et al. Systematic differences in treatment effect estimates between propensity score methods and logistic regression. Int J Epidemiol. 2008;37:1142–1147.
Worni M, Guller U, Shah A, et al. Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the nationwide inpatient sample from 2001 to 2008. Obes Surg. 2012;22:220–229.
Amorim-Cruz F, Santos-Sousa H, Ribeiro M, et al. Risk and prophylactic management of gallstone disease in bariatric surgery: a systematic review and a Bayesian meta-analysis. J Gastrointest Surg. 2023;27:433–448.
Clapp B, Lee I, Liggett E, et al. Are concomitant operations during bariatric surgery safe? An analysis of the MBSAQIP Database. Obes Surg. 2020;30:4474–4481.
Dakour-Aridi HN, El-Rayess HM, Abou-Abbass H, et al. Safety of concomitant cholecystectomy at the time of laparoscopic sleeve gastrectomy: analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Surg Obes Relat Dis. 2017;13:934–941.
Allatif REA, Mannaerts GHH, Al Afari HST, et al. Concomitant cholecystectomy for asymptomatic gallstones in bariatric surgery—safety profile and feasibility in a large tertiary referral bariatric center. Obes Surg. 2022;32:295–301.
Blohm M, Sandblom G, Enochsson L, et al. Relationship between surgical volume and outcomes in elective and acute cholecystectomy: nationwide, observational study. Br J Surg. 2023;110:353–361.
Juo Y-Y, Khrucharoen U, Chen Y, et al. Cost analysis and risk factors for interval cholecystectomy after bariatric surgery: a national study. Surg Obes Relat Dis. 2018;14:368–374.
Cunningham RM, Jones KT, Kuhn JE, et al. Asymptomatic cholelithiasis and bariatric surgery: a comprehensive long-term analysis of the risks of biliary disease in patients undergoing primary roux-en-Y gastric bypass. Obes Surg. 2021;31:1249–1255.
Guzmán HM, Sepúlveda M, Rosso N, et al. Incidence and risk factors for cholelithiasis after bariatric surgery. Obes Surg. 2019;29:2110–2114.
Stampfer MJ, Maclure KM, Colditz GA, et al. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr. 1992;55:652–658.